spec sheet10 rows
MiPLA (N-methyl-N-isopropyl lysergamide) is a close structural analog of LSD in which one of the two amide N-ethyl groups is replaced by a methyl and an isopropyl substituent. Like other lysergamide psychedelics, its effects are attributed principally to partial agonism at the 5-HT2A serotonin receptor. In the mouse head-twitch response assay, a validated behavioral proxy for 5-HT2A activation, MiPLA produced a median effective dose of approximately 422 nmol/kg, indicating potency somewhat below that of LSD while remaining within the range of active lysergamides. It has appeared on the recreational blotter market as an uncontrolled LSD substitute, prompting analytical work to distinguish it from LSD and the isomeric LAMPA; reported experiences describe a comparatively shorter and milder classical psychedelic state.
- Classic lysergamide headspace
- Often reported as smoother than LSD
- Visual and mood changes
- Somewhat shorter duration
- Potent 5-HT2A agonist lysergamide, roughly half LSD's potency
- Anxiety or confusion
- Pupil dilation and wakefulness
- Nausea during onset
Mechanism
MiPLA acts as a partial at the receptor, the main driver of the classic psychedelic state, and like other lysergamides it also engages 5-HT2C, , and dopaminergic sites to a lesser degree. The methyl/isopropyl amide substitution keeps it a potent 5-HT2A while modestly reducing potency relative to LSD. The effect is a functional change in serotonergic signaling rather than any toxic action on tissue.
receptor fingerprint
receptorpartial agonist
5-HT2C receptoragonist
receptoragonist
Safetyrisks and cautions, not medical advice
As a lysergamide, MiPLA is physiologically low in toxicity but psychologically powerful, so mindset and setting matter; it can trigger anxiety, confusion, or lasting distress in vulnerable people. Anyone with a personal or family history of psychosis or bipolar disorder should avoid it, and it should not be combined with MAOIs or strongly serotonergic drugs (serotonin toxicity) or with lithium or tramadol (seizure reports). Because it is a newer research chemical, its long-term safety is essentially unstudied. Not medical advice.
Subjective profileweighing the evidence above
It reads as a gentler LSD and the pharmacology supports that, but smoother is not the same as better characterised; this is a newer research chemical with essentially no long-term data. The standard lysergamide exclusions apply: no MAOIs, no lithium or tramadol, not with a psychosis history.
Resources
This entry is here for reference.
Research
- 1994first citedDrug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives
- 2022most recentSeparating the wheat from the chaff: Observations on the analysis of lysergamides LSD, MIPLA, a…
- 1.Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives
- 2.Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA)
- 3.Separating the wheat from the chaff: Observations on the analysis of lysergamides LSD, MIPLA, and LAMPA.
3 listed here; entry last updated July 2026
Reviews
My notesprivate to this device
FAQ
Is MiPLA the same as LSD?
No; it is a distinct analog with a methyl and isopropyl on the amide instead of two ethyls, and it tends to be somewhat less potent and shorter.
How does it work?
Mainly by partially activating the 5-HT2A serotonin receptor, the same core mechanism as other classic psychedelics.
Is it well studied?
No; it is a research chemical with little human data, so treat any margins conservatively.
Limitations of the evidence
- Poorly studied long-term profile
Adverse effects
- Anxiety or confusion
- Pupil dilation and wakefulness
- Nausea during onset